Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023)
Gain Therapeutics (GANX) posted quarterly EBITDA Margin of 9477.68% for Q1 2023, down 217093.0% year-over-year from N/an in Q1 2022, and down 115.52% quarter-over-quarter from 61076.58% in Q4 2022.
Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023) Analysis & Trends
Gain Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 9477.68% for Q1 2023.
- In Q1 2023, EBITDA Margin fell 217093.0% year-over-year to 9477.68%; the TTM figure through Dec 2023 stood at 40328.26% (down 2692578.0% YoY), while the FY2023 annual figure was 40328.26%, down 2692578.0% from the prior year.
- EBITDA Margin for Q1 2023 stood at 9477.68%, down from 61076.58% in the prior quarter.
- The five-year high for EBITDA Margin was 61076.58% in Q4 2022, with the low at 46819.42% in Q1 2021.
- The 4-year median for EBITDA Margin is 8916.35% (2020), against an average of 8491.39%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin sank 3914281 bps in 2021, then soared 8750360 bps in 2022.
- Gain Therapeutics' EBITDA Margin stood at 17678.47% in 2020, then slumped by 49 bps to 26427.02% in 2021, then soared by 331 bps to 61076.58% in 2022, then tumbled by 116 bps to 9477.68% in 2023.
- Business Quant data shows GANX's EBITDA Margin at 9477.68% in Q1 2023, 61076.58% in Q4 2022, and 5442.98% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Gain Therapeutics | 87.51 Mn | 87.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -9,477.68% |
| Dec 31, 2022 | 61,076.58% |
| Jun 30, 2022 | -5,442.98% |
| Mar 31, 2022 | -7,306.75% |
| Dec 31, 2021 | -26,427.02% |
| Sep 30, 2021 | -16,953.46% |
| Jun 30, 2021 | -4,603.35% |
| Mar 31, 2021 | -46,819.42% |
| Dec 31, 2020 | -17,678.47% |
| Sep 30, 2020 | -12,232.51% |
| Jun 30, 2020 | -8,355.01% |
| Mar 31, 2020 | -7,676.61% |